A significant higher apoptosis rate of mural granulosa cells was correlated with worse ovarian response, with fewer egg and embryo numbers in IVF/ICSI, as well as with age. Early apoptosis rate of cumulus cells might also have influence on clinical pregnancy.
with the oocyte across the zona pellucida, while the mural granulosa cells are separated from the oocyte by the cumulus cells and by the antral cavity filled with follicular fluid. Both the mural granulosa cells and the cumulus cells produce and secrete steroidal hormones as well as growth factors into the follicular fluid [9].

Higher apoptosis of granulosa cells has been associated with a higher percentage of empty follicles, fewer oocytes retrieved, and poorer quality of oocytes and embryos. Apoptosis of granulosa cells has been reported to have a negative effect on pregnancy rate and live birth rate with in vitro fertilization (IVF) [10, 11]. An increase of cumulus cell apoptosis has been reported in patients over 40 years old [12]. However, apoptosis in granulosa cells has been shown not to be related to follicular quality, oocyte maturity, or fertilizability in ICSI [13]. A recent study indicates that there is less apoptosis of granulosa cells in women with diminished ovarian reserve [14]. Thus, it is still controversial whether apoptosis of granulosa cells has an influence on oocyte quality and ovarian response. The majority of these studies focused on only granulosa cells isolated from follicular fluid during oocyte retrieval. Even though mural granulosa cells and cumulus cells begin in primordial, primary, secondary stage as a single-cell type, during folliculogenesis, especially during antral follicle and preovulatory follicle, they express different gene expression profiles [15]. A recent study on microRNAs shows that there are different expression profiles in mural granulosa cells rather than cumulus cells of young women with diminished ovarian reserve [16]. Apoptosis of mural granulosa cells and cumulus cells may have a different influence in women with normal ovarian reserve versus those with diminished ovarian reserve.

In this paper, we report a prospective cohort study to investigate multiple factors in the relationship between apoptosis of mural granulosa cells and cumulus cells, with clinical outcomes of patients with normal ovarian reserve and diminished ovarian reserve undergoing in vitro fertilization/intracytoplasmic sperm injection ((IVF/ICSI). Also, in order to better define the correlation between granulosa cell apoptosis and follicular fluid steroidal hormones, we analyzed the levels of steroids, including anti-Müllerian hormone (AMH), estradiol (E2), luteinizing hormone (LH), progesterone (P), and testosterone (T) in follicular fluid.

Materials and methods

Patients

The design of this prospective cohort study was approved by the IRB at Sixth Affiliated hospital of Sun Yat-sen University. Patients undergoing egg retrievals at the Center of Reproductive Medicine, Sixth Affiliated hospital were consented for collection and use of their discarded follicular fluid and granulosa cells for research purposes. A total of 164 women aged 21–46 years undergoing IVF/ICSI from October 2015 to June 2016 were included in this study. Enrolled patients met the following inclusion criteria: (i) adequate visualization of the ovaries on transvaginal ultrasound scans, (ii) no endocrine disorders and or history of ovarian surgery affecting the ovaries or gonadotropin/sex steroid secretion, and (iii) no current hormone therapy. Primary outcome was clinical pregnancy rate defined as a positive fetal heart activity on 12-week ultrasound. We further defined this patient population as two subgroups, normal ovarian reserve and diminished ovarian reserve. Diminished ovarian reserve was defined using a modification of the Bologna criteria. Patients with two or more of the following were classified as diminished ovarian reserve: (1) basal serum AMH < 2 ng/mL, day 3 follicle-stimulating hormone (FSH) > 10 IU/L, and antral follicle count ≥ 6. There were 118 patients in the normal ovarian reserve group and 46 in the diminished ovarian reserve group.

Basic hormonal measurements and antral follicle count measurement

Whole blood specimens were collected on menstrual day 3. Basic serum AMH, estradiol (E2), luteinizing hormone (LH), progesterone (P4), and testosterone (T) levels were measured by electrochemiluminescence immunoassay (ECLIA) (Roche Diagnostics GmbH, Mannheim, Germany). Antral follicle count was recorded with transvaginal ultrasound in both ovaries by measuring all visible follicles ≥ 3 mm in diameter; cystic morphologies larger than 12 mm were excluded.

Stimulation protocol

Patients were assigned to long protocols, antagonist protocols, or minimal stimulation protocols based on the patient’s age, cause of infertility, basal AMH/FSH level, antral follicle count, previous ovarian response to gonadotropin, body mass index, and physician preference.

For long protocols, pituitary downregulation via administration of a gonadotrophin-releasing hormone agonist (GnRH-a) (Decapeptyl; Ipsen Pharmaceuticals, France) was performed in the mid-luteal phase before stimulation cycle. After 14 days, ovarian stimulation was started using recombinant FSH (Gonal-F; Merck Serono, Switzerland) injection. The starting dose varied from 150 to 375 IU based on patient’s age, AMH, antral follicle count, and BMI. Doses were further adjusted according to ovarian response, which was periodical monitored with transvaginal ultrasound and serum E2 and FSH.

For antagonist protocols, ovarian stimulation was started using 150 IU to 375 IU recombinant FSH (Gonal-F, Merk Serono, Switzerland) on day 3 of menstrual cycle.
growth was monitored by transvaginal ultrasound, and serum E2, FSH, and LH levels were tested periodically. A dose of 0.25 mg GnRH-antagonist, cetrorelix (Cetrotide, Merck Serono; or Orgalutran, MSD) was initiated on day 6 of the cycle or when the leading follicle reached 14 mm in diameter. GnRH-antagonist was injected subcutaneously daily until hCG trigger.

For minimal stimulation protocols, patients were given 50 mg of clomiphene citrate or 2.5 mg of letrozole for 5 days. FSH of 75–150 IU (Gonal-F; Merck Serono, Switzerland) was injected every 2 days, and GnRH-antagonist was injected subcutaneously daily when the leading follicle reached 18 mm in diameter. Ultrasound-guided transvaginal oocyte retrieval was performed 34–36 h after hCG trigger.

The patients were administered 6000–10,000 IU of hCG when the leading follicle reached 18 mm in diameter with at least three follicles >16 mm in diameter. Ultrasound-guided transvaginal oocyte retrieval was performed 34–36 h after hCG administration.

**Mural granulosa cells, cumulus cells, and follicular fluid collection**

Mural granulosa cells, cumulus cells, and follicular fluid were obtained via ultrasound-guided transvaginal oocyte retrieval, which was performed 34–36 h after hCG injection. Aspirate from the first punctured follicle was used to collect mural cells and follicular fluid. Cumulus cells were manually trimmed from the cumulus-oocyte complex by the embryologist. Cumulus cells and follicular fluid were transferred to round-bottom polystyrene tubes separately. The oocyte was transferred to the fertilization dish and continued through standard embryology lab procedures for either IVF or ICSI and embryo culture. The follicular aspiration from the rest of follicles (except the first punctured follicle), after removal of oocyte-cumulus complexes, was pooled and stored in 50-mL conical polypropylene tubes (BD Falcon, Becton Dickinson, Franklin Lakes, NJ) for mural granulosa cell isolation.

Mural granulosa cells, cumulus cells, and follicular fluid were transferred to the lab for further processing in 1 h. Mural granulosa cells were isolated from follicular aspirates using Ficoll methods. Follicular fluids that contained mural granulosa cells were washed three times with cold sterile phosphate-buffered saline (PBS) at 500 g for 5 min at room temperature. Four milliliters of PBS was added to pellets and diluted solution was layered carefully on 6 mL of Ficoll-Paque (GE Healthcare, Uppsala, Sweden). The samples were centrifuged at 1000g for 25 min at room temperature. The cells that were in the interface were collected for apoptosis staining. Follicular fluid was centrifuged at 2500g for 10 min, and the supernatants were transferred to 1.5-mL microcentrifuge tube and stored at –80 °C.

**Annexin V-FITC/PI apoptosis staining and flow cytometry**

To determine apoptosis of mural granulosa cells and cumulus cells, FITC Annexin V-FITC/PI double staining was evaluated using the FITC Annexin V Apoptosis Detection Kit (BD Biosciences, San Diego, CA). Single-cell suspensions of mural granulosa cells and cumulus cells were washed twice with cold PBS and then resuspended in 1× binding buffer at a concentration of 1 × 10^6 cells/mL. Specimens were stained for 15 min with Annexin V-FITC and propidium iodide (PI) at room temperature in the dark and analyzed by flow cytometry (BD Bioscience FacsCanto II, San Diego, CA) within 1 h. At least 10,000 cells were analyzed per patient. The percentage distribution of viable, early apoptotic, late apoptotic, and necrotic cells was calculated using FlowJo v10 (Fig. 1).

**Intrafollicular hormone assay**

Follicular fluid was thawed and equilibrated to room temperature for 30 min and mixed well before analysis. Follicular fluid AMH, E2, P4, T were measured by ECLIA (Roche Diagnostics GmbH, Mannheim, Germany) as previously described.

**Embryo transfer and luteal phase support**

The retrieved oocytes were fertilized by IVF or ICSI. Fresh transfers were performed either on D3 or D5 based on patients’ preference and physician’s suggestion. We only included the first frozen embryo transfer (FET) cycle if the patient did not perform fresh transfer in this oocyte retrieval cycle. In the FET group, either D3 blastomere or D5/6 blastocyst embryo was thawed and transferred with programmed estrogen/progesterone uterine replacement 2 months after oocyte retrieval. In both groups, the luteal phase was supported by transvaginal micronized P, 200 mg three times daily (Uterogestan; Besins Iscovesco, Paris, France) or P in oil, 100 mg IM.

**Follow-up**

Serum hCG was measured 14 days after embryo transplantation. Transvaginal ultrasound was performed to determine intrauterine pregnancy, gestational sac number, and embryo heart activity at 7 weeks if the serum hCG test is positive. Telephone interviews were performed to collect live birth data.

**Evaluated parameters**

For the patients included in the study, the following characteristics were recorded: age, infertility type, duration of
infertility, previous pregnancy, previous delivery, previous miscarriage, body mass index (BMI), basal serum FSH, LH, E₂, T, and AMH levels. Parameters associated with ovulation stimulation and ovarian response were recorded as following: controlled ovarian hyperstimulation protocol, gonadotrophin usage day, total dose of gonadotrophin, number of oocytes retrieved. Evaluated parameters associated with oocyte developmental competence including: metaphase II (MII) oocyte number, oocyte maturation rate, fertilization rate, two pronuclei cleavage number (2pn), 2pn cleavage rate, day 3 embryo number, day 3 good embryo number (day 3 good embryo defined as 6 to 10 cell blastomere on day 3, <20% fragmentation, no multi-nucleation), blastocyst formation rate, transfer, and freezing embryo number. Parameters associated with embryo transfer included embryo number, clinical pregnancy rate, implantation rate, clinical pregnancy rate, and live birth rate. All the above parameters were evaluated in association with mural granulosa cells, cumulus, and follicular fluid hormonal levels.

**Statistical analyses**

All statistical analyses were performed using SPSS 18.0 software (SPSS Inc., USA). Descriptive parameters and patient characteristics were reported as mean ± standard deviation (SD) or median (range) values depending on variable distribution. Comparisons were made by using the independent sample t test for normal distribution variables and were compared using nonparametric Mann-Whitney U test for non-normal distribution variables. Chi square test and correlation analysis were used. Correlation coefficients (r) and the exact p values were calculated. A difference with P < 0.05 (two-sided) was considered statistically significant.

**Results**

**Information of patients**

Characteristics of patients from normal ovarian reserve and diminished ovarian reserve group are shown in Table 1. There were significant differences in age, previous history of pregnancies, deliveries, and miscarriage between two groups. BMI, basal serum FSH, LH, T, AMH, and antral follicle count. FF AMH, E₂, and P levels also show differences between two groups, with poorer outcomes in the diminished ovarian reserve group.

**Apoptosis of mural granulosa cells, cumulus cells, and follicular fluid hormones**

The percentages of necrosis, early apoptosis, late apoptosis, and total apoptosis rate of mural granulosa cells and cumulus cells in relation to the normal ovarian reserve or diminished ovarian reserve group are shown in Table 2. The median of early, late, and total apoptosis rate in normal ovarian reserve group were 1.20% (0.42–3.72%), 1.71% (0.37–5.09%), and 4.68% (1.62–10.30%), respectively. The median of early, late, and total apoptosis rate in diminished ovarian reserve group were 2.16% (1.25–8.12%), 5.24% (1.54–9.79%), and 9.67% (4.85–16.89%), respectively. Apoptosis of mural granulosa cells including early, late, and total apoptosis was all increased in diminished ovarian reserve group when compared with normal ovarian reserve group (P < 0.01 (two-sided), Mann-Whitney U test). While there were no differences in total cumulus cell apoptosis between normal ovarian reserve and diminished ovarian reserve, follicular fluid AMH in normal ovarian reserve group and diminished ovarian reserve were 3.48 ng/mL (2.06–5.84) and

![Fig. 1 Annexin V-FITC/PI staining](image-url)
1.42 ng/mL (0.98–2.43). Follicular fluid P in normal ovarian reserve group and diminished ovarian reserve were 18,900 ng/mL (12,945–45,380) and 13,800 ng/mL (10,350–16,950). Follicular fluid E2 in normal ovarian reserve group and diminished ovarian reserve were 1,628,100 ng/mL (478,044–872,500) and 893,500 ng/mL (614,310–1,085,000), respectively. Follicular fluid AMH (P < 0.0001) and P (P < 0.05) were significantly decreased while follicular fluid E2 (P < 0.05) were increased in diminished ovarian reserve group.

**Ovarian response-related results, laboratory results, and clinical outcomes**

Parameters associated with ovulation stimulation, ovarian response, laboratory results, and clinical outcomes are shown in Table 3. Parameters associated with ovulation stimulation and ovarian response such as gonadotrophin usage day (7 vs 11; diminished ovarian reserve vs normal ovarian reserve, P < 0.0001), total dose of gonadotrophin (1200 vs 1650; diminished ovarian reserve vs normal ovarian reserve, P < 0.05), and number of oocytes retrieved (3 vs 14; diminished ovarian reserve vs normal ovarian reserve, P < 0.001) were significantly decreased in diminished ovarian reserve group. Laboratory results including 2pn number (1 vs 8; diminished ovarian reserve vs normal ovarian reserve, P < 0.001), 2pn cleavage number (1 vs 8; diminished ovarian reserve vs normal ovarian reserve, P < 0.001), D3 embryo number (1 vs 6; diminished ovarian reserve vs normal ovarian reserve, P < 0.001), D3 good embryo number (1 vs 5; diminished ovarian reserve vs normal ovarian reserve, P < 0.001), D3 good embryo rate (67.54% vs 33.33%; diminished ovarian

### Table 1 Comparison of variable parameters between NOR and DOR group

| Parameters                              | NOR (n = 118) | DOR (n = 46) | P value |
|-----------------------------------------|---------------|--------------|---------|
| Age (year)                              | 29 (27–32)    | 40 (32.75–43)| < 0.0001|
| Duration of infertility (year)          | 3 (2–5)       | 2.5 (1–5.25)| ns      |
| Number of pregnancies (n)               | 0 (0–1)       | 1.5 (0.75–2) | < 0.0001|
| Number of deliveries (n)                | 0 (0–0)       | 0 (0–1)     | < 0.0001|
| Previous miscarriage (n)                | 0 (0–1)       | 1 (0–1.25)  | < 0.0001|
| BMI (kg/m²)                             | 21.00 (19.57–23.16)| 23.04 (20.38–24.96)| < 0.005|
| Basal serum FSH (mIU/mL)                | 6.39 (5.69–7.34)| 8.61 (6.93–10.75)| < 0.0001|
| Basal serum E2 (pmol/L)                 | 38.10 (28.70–47.10)| 37.1 (23.4–53.1)| ns      |
| Basal serum LH (mIU/mL)                 | 5.56 (4.09–7.76)| 4.47 (3.09–6.33)| < 0.05  |
| Basal serum T (nmol/L)                  | 0.28 (0.20–0.36)| 0.22 (0.11–0.29)| < 0.05  |
| Basal serum AMH (ng/mL)                 | 4.94 (3.20–7.59)| 0.73 (0.34–1.09)| < 0.0001|
| AFC                                     | 14 (9–20)     | 4 (2–5)     | < 0.0001|

All parameters were shown as median (interquartile range (IQR)). P < 0.05 (two-sided) was considered statistically significant, Mann-Whitney U test was used.

**BMI** body mass index, **AFC** antral follicle count

### Table 2 Comparison of apoptosis of MGCs, CCs and FF hormones between NOR and DOR group

| Parameters                              | NOR (n = 118) | DOR (n = 46) | P value |
|-----------------------------------------|---------------|--------------|---------|
| MGCs necrosis rate (%)                  | 3.66 (0.70, 9.94)| 5.15 (1.19, 13.52)| ns      |
| MGCs early apoptosis rate (%)           | 0.49 (0.22–2.32)| 1.26 (0.48–1.80)| < 0.0001|
| MGCs late apoptosis rate (%)            | 1.96 (0.28–5.59)| 4.88 (2.02–9.98)| < 0.001  |
| MGCs total apoptosis rate (%)           | 2.07 (0.87–6.63)| 5.55 (3.80–11.39)| < 0.0001|
| CCs necrosis rate (%)                   | 1.14 (0.084–1.86)| 1.07 (0.44–2.10)| ns      |
| CCs early apoptosis rate (%)            | 0.23 (0.045–0.72)| 0.29 (0.20–0.60)| ns      |
| CCs late apoptosis rate (%)             | 4.27 (0.72–13.40)| 6.63 (2.69–11.80)| ns      |
| CCs total apoptosis rate (%)            | 5.60 (1.44–14.42)| 6.98 (3.12–11.99)| ns      |
| FF AMH (ng/mL)                          | 3.48 (2.06–5.84)| 1.42 (0.98–2.43)| < 0.0001|
| FF E2 (pmol/L)                          | 628,100 (478,044–872,500)| 893,500 (614,310–1,085,000)| < 0.05|
| FF P (ng/mL)                            | 18,900 (12,945–45,380)| 13,800 (10,350–16,950)| < 0.05|
| FF T (nmol/L)                           | 5.30 (4.00–8.40)| 5.99 (4.26–8.34)| ns      |

All parameters were shown as median (interquartile range (IQR)). P < 0.05 (two-sided) was considered statistically significant, Mann-Whitney U test was used.

### Table 3 Comparison of apoptosis of MGCs, CCs and FF hormones between NOR and DOR group

| Parameters                              | NOR (n = 118) | DOR (n = 46) | P value |
|-----------------------------------------|---------------|--------------|---------|
| MGCs necrosis rate (%)                  | 3.66 (0.70, 9.94)| 5.15 (1.19, 13.52)| ns      |
| MGCs early apoptosis rate (%)           | 0.49 (0.22–2.32)| 1.26 (0.48–1.80)| < 0.0001|
| MGCs late apoptosis rate (%)            | 1.96 (0.28–5.59)| 4.88 (2.02–9.98)| < 0.001  |
| MGCs total apoptosis rate (%)           | 2.07 (0.87–6.63)| 5.55 (3.80–11.39)| < 0.0001|
| CCs necrosis rate (%)                   | 1.14 (0.084–1.86)| 1.07 (0.44–2.10)| ns      |
| CCs early apoptosis rate (%)            | 0.23 (0.045–0.72)| 0.29 (0.20–0.60)| ns      |
| CCs late apoptosis rate (%)             | 4.27 (0.72–13.40)| 6.63 (2.69–11.80)| ns      |
| CCs total apoptosis rate (%)            | 5.60 (1.44–14.42)| 6.98 (3.12–11.99)| ns      |
| FF AMH (ng/mL)                          | 3.48 (2.06–5.84)| 1.42 (0.98–2.43)| < 0.0001|
| FF E2 (pmol/L)                          | 628,100 (478,044–872,500)| 893,500 (614,310–1,085,000)| < 0.05|
| FF P (ng/mL)                            | 18,900 (12,945–45,380)| 13,800 (10,350–16,950)| < 0.05|
| FF T (nmol/L)                           | 5.30 (4.00–8.40)| 5.99 (4.26–8.34)| ns      |

All parameters were shown as median (interquartile range (IQR)). P < 0.05 (two-sided) was considered statistically significant, Mann-Whitney U test was used.
Total apoptosis of mural granulosa cells were negatively related with hCG day E2 \( (r = -0.405, P < 0.001) \), gonadotrophin usage day \( (r = -0.205, P < 0.01) \), antral follicle count \( (r = -0.240, P < 0.01) \), number of oocytes retrieved \( (r = -0.361, P < 0.0001) \), number of MII oocytes \( (r = -0.427, P < 0.001) \), 0pn number \( (r = -0.281, P < 0.0001) \), 2pn number \( (r = -0.281, P < 0.0001) \), 2pn cleavage number \( (r = -0.284, P < 0.0001) \), D3 embryo number \( (r = -0.277, P < 0.0001) \), D3 good embryo number \( (r = -0.263, P < 0.0001) \), and freezing embryo number \( (r = -0.333, P < 0.0001) \). The lower the apoptosis rate of the mural granulosa cells, the greater was the ovarian reserve and clinical outcome. Total apoptosis of mural granulosa cells were positively related to age \( (r = 0.251, P < 0.001) \) and day 3 FSH \( (r = 0.222, P < 0.01) \).

### Apoptosis of mural granulosa cells, cumulus cells, and follicular fluid hormones in different age groups

Since we found a positive correlation between mural granulosa cell apoptosis rate and age, we further analyzed the apoptosis and follicular fluid hormone results in different age groups (Table 4). The percentages of early apoptosis, late apoptosis, and total apoptosis rate of mural granulosa cells were significantly increased in women age \( \geq 37 \) years old. Follicular fluid AMH was significantly decreased in women age \( \geq 37 \) years old.

### Comparison of parameters between clinical pregnant and non-pregnant group

The cumulus cells early apoptosis rate in the clinical pregnant group and the non-pregnant group were 0.13% (0.032–0.86%) and 0.37% (0.19–0.69%), respectively (Table 5).
Follicular fluid $E_2$ in the pregnant group and non-pregnant group were 602,497 pmol/L (468,066–835,750) and 716,750 pmol/L (0.19–0.69%), respectively. The cumulus cells early apoptosis rate and follicular fluid $E_2$ were significantly higher in non-pregnant group compared with the clinical pregnant group. Good blastocyst number and blastocyst formation rate were significantly higher in the clinical pregnant group.

### Discussion

Apoptosis of mural granulosa cells and cumulus cells are different in patients with diminished vs normal ovarian reserve. There is significantly less mural granulosa cell apoptosis with normal ovarian reserve. Likewise with diminished ovarian reserve, there is much greater mural granulosa cell apoptosis. Interestingly, there is no such difference in total cumulus cell apoptosis, but the early apoptosis rate is also correlated with poorer outcomes when comparing the clinical pregnant group to non-pregnant group. This may be the first paper to compare mural granulosa cells to cumulus cells in patients with diminished or normal ovarian reserve. Clearly, as the ovary ages, the poorer results with IVF/ICSI can be correlated with increased apoptosis of the mural granulosa cells. One could speculate that the aging of the oocyte and the aging of the somatic supporting cells are related.

Apoptosis, or programmed cell death, is a normal physiologic process for removal of unwanted cells [17]. One of the earlier events of apoptosis includes translocation of membrane phosphatidylserine (PS) from the inner side of the plasma membrane to the surface. Annexin V, a calcium-dependent phospholipid-binding protein, has high affinity for PS; therefore, fluorescently labeled annexin V can be used for the detection of exposed PS using flow cytometry [18]. By co-staining with propidium iodide (PI) and analyzing with flow cytometry, cell population can be further classified as necrotic cells (annexin V-PI+), early apoptotic cells (annexin V + PI−), late apoptotic cells (annexin V + PI+), and viable cells (annexin V − PI−). Annexin V/PI staining is one of the most commonly used assays to measure apoptosis and necrosis [17, 18]. Other methods for measuring programmed cell death include array transcriptome analysis, and autophagy, and mitophagy, but are not included in this paper.

Diminished ovarian reserve is a term related to both oocyte quantity and quality [19, 20]. However, it is much easier and direct to measure oocyte yield than oocyte quality in diminished ovarian reserve patients in clinical practice. Our study shows higher mural granulosa cell apoptosis including early, late, and total apoptosis, associated with diminished ovarian reserve. Also, mural granulosa cell apoptosis was negatively correlated with parameters associated with ovarian stimulation and ovarian response, including hCG day $E_2$, gonadotrophin usage day, number of oocytes retrieved.

Mural granulosa cell apoptosis when combined with age and basal serum AMH can be used as a marker to predict number of oocytes retrieved in a linear regression model ($R = 0.702$, $P < 0.005$) (Supplemental Table 1). Less mural granulosa cell apoptosis is associated with better ovarian response and higher oocyte yield in IVF/ICSI.

The question of whether mural granulosa cell apoptosis has direct relationship with oocyte quality is much more difficult to answer in the studies thus far reported. Sadraie et al. [21] found a significantly higher incidence of apoptotic cells in

### Table 4  Comparison of apoptosis of MGCs, CCs, and FF hormones in different age groups

| Parameters                     | < 30 ($n = 64$) | 30–37 ($n = 70$) | ≥ 37 ($n = 30$) | $P$ value |
|-------------------------------|----------------|-----------------|----------------|-----------|
| MGCs necrosis rate (%)        | 5.33 (1.00–15.40) | 3.51 (0.55–10.29) | 3.61 (0.75–8.40) | ns        |
| MGCs early apoptosis rate (%) | 0.45 (0.20–1.00)   | 0.62 (0.25–1.46)   | 1.30 (0.53–2.40)   | < 0.0001 |
| MGCs late apoptosis rate (%)  | 2.08 (0.29–5.67)   | 2.26 (0.42–4.21)   | 6.40 (2.33–15.70)  | < 0.05   |
| MGCs total apoptosis rate (%) | 2.85 (0.83–6.42)   | 2.77 (1.00–6.69)   | 6.91 (3.92–17.05)  | < 0.0005 |
| CCs necrosis rate (%)         | 1.24 (0.20–2.01)   | 0.49 (0.06–1.70)   | 1.07 (0.44–2.17)   | ns        |
| CCs early apoptosis rate (%)  | 0.21 (0.04–0.66)   | 0.31 (0.10–1.06)   | 0.30 (0.20–1.03)   | ns        |
| CCs late apoptosis rate (%)   | 4.46 (0.78–13.75)  | 5.83 (0.72–11.8)   | 5.76 (2.65–10.52)  | ns        |
| CCs total apoptosis rate (%)  | 5.60 (1.77–15.00)  | 6.79 (1.44–12.18)  | 6.80 (3.07–10.90)  | ns        |
| FF AMH (ng/mL)                | 3.66 (2.33–6.22)   | 2.57 (1.44–4.30)   | 1.77 (0.80–2.66)   | < 0.05   |
| FF E2 (pmol/L)                | 692,885 (491,558–988,625) | 618,862 (470,400–893,500) | 816,500 (615,000–1,157,250) | ns        |
| FF P4 (ng/mL)                 | 21,010 (14,100–46,000) | 15,000 (12,000–29,990) | 14,400 (9750–17,100) | ns        |
| FF T (nmol/L)                 | 5.80 (4.27–8.68)   | 5.18 (3.99–11.85)  | 5.99 (3.63–8.34)   | ns        |

All parameters were shown as median (interquartile range (IQR)). $P < 0.05$ (two-sided) was considered statistically significant, Kruskal-Wallis $H$ test was used.
mural granulosa cells in women > 40 years old with less oocytes retrieved and less mature oocytes. Corn et al. [38] reported that apoptotic processes seem to impair oocyte maturation and lower the chance of blastocyst formation. However, Jancar et al. [23] reported that apoptosis and reactive oxygen species production in granulosa cells have no significant impact on fertilization and do not correlate with the development of blastocysts. In our study, we found that there is a higher

| Parameters                        | Clinical pregnant (n = 62) | Non-pregnant (n = 66) | P value |
|-----------------------------------|---------------------------|-----------------------|---------|
| Age (year)                        | 29 (27.75–32)             | 30 (27–33)            | ns      |
| Duration of Infertility (year)     | 3 (2–4)                   | 3 (2–5)               | ns      |
| Number of pregnancies(n)          | 1 (0–1)                   | 1 (0–1)               | ns      |
| Number of deliveries (n)          | 0 (0–0)                   | 0 (0–0)               | ns      |
| Previous miscarriage (n)          | 0 (0–1)                   | 1 (0–1)               | ns      |
| BMI (kg/m²)                       | 21.37 (19.99–23.77)       | 20.84 (19.08–23.01)   | ns      |
| Basal serum FSH (mIU/mL)          | 6.57 (5.36–7.35)          | 6.62 (5.73–7.55)      | ns      |
| Basal serum E2 (pmol/L)           | 37.3 (28.55–47.7)         | 37.1 (26.3–44.3)      | ns      |
| Basal serum LH (mIU/mL)           | 5.52 (4.03–7.54)          | 5.26 (3.96–8.39)      | ns      |
| Basal serum T (nmol/L)            | 0.28 (0.20–0.36)          | 0.27 (0.19–0.35)      | ns      |
| Basal serum AMH (ng/mL)           | 4.34 (2.14–7.46)          | 3.76 (1.62–6.03)      | ns      |
| AFC                               | 13.5 (8–20)               | 10.5 (6–16)           | 0.062   |
| MGCs necrosis rate (%)            | 7.29 (0.65–11)            | 4.06 (1.00–14.8)      | ns      |
| MGCs early apoptosis rate (%)     | 0.58 (0.29–1.08)          | 0.63 (0.22–1.45)      | ns      |
| MGCs late apoptosis rate (%)      | 2.75 (0.67–6.31)          | 2.36 (0.06–5.68)      | ns      |
| MGCs total apoptosis rate (%)     | 3.33 (1.04–7.69)          | 3.28 (0.74–6.69)      | ns      |
| CCs necrosis rate (%)             | 0.87 (0.084–1.73)         | 1.28 (0.23–2.36)      | ns      |
| CCs early apoptosis rate (%)      | 0.13 (0.032–0.86)         | 0.37 (0.19–0.69)      | < 0.05  |
| CCs late apoptosis rate (%)       | 2.46 (0.47–13.4)          | 6.63 (1.36–14.0)      | ns      |
| CCs total apoptosis rate (%)      | 2.63 (0.56–14.42)         | 8.71 (3.81–14.61)     | 0.052   |
| FF AMH (ng/mL)                    | 3.33 (1.83–4.98)          | 2.91 (1.14–5.28)      | ns      |
| FF E2 (pmol/L)                    | 602,497 (468,066–835,750) | 716,750 (612,033–942,250) | < 0.05  |
| FF P (ng/mL)                      | 17,700 (12,300–45,935)    | 17,700 (12,697.5–29,052.5) | ns      |
| FF T (nmol/L)                     | 5.26 (3.5–8)              | 5.29 (4.38–8.48)      | ns      |
| GN day (day)                      | 11 (9–12)                 | 10 (9–12)             | ns      |
| Total GN Dosage (IU)              | 1650 (1275–2200)          | 1650 (1200–2287.5)    | ns      |
| hCG day E2(pmol/L)                | 4759 (2943–7258.5)        | 2691 (1267–4812)      | 0.069   |
| OPU egg number                    | 13 (8–17.25)              | 10.5 (6–18)           | ns      |
| MII egg number                    | 9 (5.5–13.5)              | 6 (3–13)              | ns      |
| 2pn number                        | 8 (5–11.25)               | 6 (3.75–11)           | ns      |
| Fertilization rate                | 75.00 (60.00–83.93))      | 67.26 (57.14–83.33)   | ns      |
| 2pn cleavage number               | 8 (5–11)                  | 6 (3.75–11)           | ns      |
| 2pn cleavage rate (%)             | 90.69 (78.37–100)         | 93.30 (75–100)        | ns      |
| D3 embryo number                  | 6 (4–9)                   | 5 (2–9)               | ns      |
| D3 good embryo number             | 5.5 (23–8)                | 4 (2–6.25)            | 0.050   |
| D3 good embryo rate (%)           | 70.71 (59.29–94.23)       | 70.98 (41.25–83.55)   | ns      |
| Culture D3 embryo number          | 6 (4–9)                   | 4 (2–9)               | ns      |
| Blastocyst number                 | 3 (2–6)                   | 3 (1–5)               | < 0.05  |
| Good blastocyst number            | 3 (1–5)                   | 2 (0–3.25)            | < 0.05  |
| Blastocyst formation rate (%)     | 55.56 (50.00–83.33)       | 41.67 (17.21–71.63)   | < 0.05  |
| Freezing embryo number            | 4 (2–6.25)                | 2 (0.5–5.5)           | 0.08    |

All parameters were shown as median (p25, p75). P < 0.05 (two-sided) was considered statistically significant, Mann-Whitney U test was used.

GN day gonadotrophin usage day, total GN dosage total dose of gonadotrophin, OPU egg number number of oocytes retrieved.
percentage of total apoptotic cells in mural granulosa cells in women ≥ 37 years old, which is consistent with Saderaie and Corn’s results. Mural granulosa cell apoptosis is negatively correlated to the number of MI oocytes, number of 2pn cleavage, number of D3 embryos, number of D3 good embryos, and number of frozen embryos. The lower the apoptosis rate of the mural granulosa cells, the greater is the mature oocyte and embryo yield. Mural granulosa cell apoptosis might possibly be not only correlated with ovarian response, but also might correlate with oocyte quality and subsequent embryo development.

There is an elaborate and complex junctional communication system which mediates the information flow between cumulus granulosa cells and oocyte within the ovarian follicle during oocyte maturation [24]. Studies have shown that mitochondrial characteristics of cumulus cells may serve as indicators of oocyte competence [25] and embryo quality [26, 27]. Transcripts and microarray experiments of cumulus cell can be used as markers of oocyte and embryo quality [27] and used in single embryo selection to increase live birth rate [28]. We found a significant increase of total mural granulosa cell apoptosis in women with diminished ovarian reserve and a negative correlation with oocyte yield, embryo development, and clinical outcome. We did not observe a significant difference of total cumulus cell apoptosis in diminished ovarian reserve when compared with normal ovarian reserve. One explanation may be that the granulosa cells are more susceptible to apoptosis in the follicle than the theca or cumulus cells [37]. In a recent paper about microRNA in young women with diminished ovarian reserve, only nine miRNAs were found to be differentially expressed in cumulus cells in young women with diminished ovarian reserve, while there were 105 miRNA differentially expressed in granulosa cells [16]. However, when we compared parameters between the clinical pregnant group and the non-pregnant group, cumulus cell early apoptosis rate was significantly lower in the pregnant group.

There were similar baseline factors including age, basal serum AMH, gonadotropin dosage, stimulation days, and retrieval oocyte number between pregnant and non-pregnant group. Higher number of D3 good embryo, good blastocyst, and blastocyst formation rate were observed in pregnant group. Even though the percentage of early apoptosis rate of cumulus cells was relatively low in both groups, it may be a sensitive marker in cumulus cell quality. When adjusting the influence of ovarian response and ovarian stimulation, early cumulus cell apoptosis might have an influence on embryo development and pregnancy.

We found that follicular fluid E2 level was significantly higher while follicular fluid P4 and AMH level was lower in diminished ovarian reserve group. Estrogens and progesterone represent the key ovarian hormones produced by the developing ovulatory follicle [29]. In our study, we found that follicular fluid contained much higher levels of E2 and P4 34–36 h after hCG trigger, consistent with other studies [30]. In follicular fluid, E2 was a negative predictor of the number of oocytes retrieved and the number of day 5 blastocysts [30]. Intrafollicular AMH levels were positively related to P4 [31]. After hCG trigger, there is an upregulation of P4 and downregulation of estradiol level in serum. Higher levels of estradiol and lower levels of progesterone in follicular fluid in women with diminished ovarian reserve may indicate a dysfunction and poor response to hCG trigger, resulting in a failure of transition between E2 and P4.

One of the deficiencies in our study is that patients were assigned to different stimulation protocols for controlled ovarian hyperstimulation according to physician’s preference. Previous studies have shown that controlled ovarian hyperstimulation protocols may affect apoptosis in cumulus cells [22, 32–35]. This may influence the apoptosis and clinical outcomes between diminished ovarian reserve and normal ovarian reserve. However, we did not observe a significant difference in granulosa cell apoptosis and follicular fluid hormones among different controlled ovarian hyperstimulation protocols in this prospective cohort (Supplemental Table 2). Thus, we combined data from different controlled ovarian hyperstimulation protocols in our analysis.

Another deficiency is that we needed to pool together the follicle fluid to isolate mural granulosa cells. It was not available to us to correlate each follicle with oocyte and embryo development [36]. But we were still able to analyze the overall mural granulosa cell apoptosis rate in women with diminished ovarian reserve. Thus, we were able to compare both mural granulosa cells and cumulus cells, with follicular fluid hormones in each patient.

Perhaps the most important deficiency in this report is that we studied only one of the many pathways to programmed cell death, i.e., annexin V-FITC/PI apoptosis staining and flow cytometry. In order to determine more clearly the relationship of apoptosis of mural and cumuluous cells to ovarian reserve and egg quality, these pathways will also need to be studied.

In conclusion, according to our data, total mural granulosa cell apoptosis (but not total cumulus cell apoptosis) is increased in women with diminished ovarian reserve, correlated with worse ovarian response, and with fewer egg and embryo numbers. Mural granulosa cell apoptosis is increased in women ≥ 37 years old. Mural granulosa cell apoptosis may be used as a marker to indicate oocyte yield and ovarian response in women undergoing IVF/ICSI. Direct relationship between granulosa cell/cumulus cell apoptosis and oocyte quality will need to be investigated in future studies. Furthermore, other pathways and methodologies of cell death in mural and granulosa cells will need to be studied.
Funding This study is supported by the National Key Science and Technology Program of China (No. 81171507) and the National Key Research and Development Program of China (No. 2017YFC1001600).

Compliance with ethical standards

Ethical standards The ethics committee of the Sixth Affiliated Hospital of Sun Yat-sen University approved this study. Informed consent from each participant was obtained in this study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol. 2017;217(2):129–40. https://doi.org/10.1016/j.ajog.2017.02.027.
2. Levi AJ, Raynault MF, Bergh PA, Drews MR, Miller BT, Scott RT Jr. Reproductive outcome in patients with diminished ovarian reserve. Fertil Steril. 2001;76(4):666–9. https://doi.org/10.1016/S0015-0282(01)02017-9.
3. Pastore LM, Young SL, Baker VL, Karns LB, Williams CD, Silverman SL. Elevated prevalence of 35–44 FMR1 trinucleotide repeats in women with diminished ovarian reserve. Reprod Sci. 2012;19(11):1226–31. https://doi.org/10.1177/1933719112446074.
4. May-Panloup P, Ferre-L’Hotellier V, Moriniere C, Marcaillou C, Lemerle S, Malinge MC, et al. Molecular characterization of corona radiata cells from patients with diminished ovarian reserve using microarray and microfluidic-based gene expression profiling. Hum Reprod. 2012;27(3):829–43. https://doi.org/10.1093/humrep/der431.
5. Griefen N, Weghofer A, Oktay K, Barad DH. Is the immunological state of abnormal autoimmune an independent risk factor for premature ovarian aging? Menopause. 2009;16(6):760–4. https://doi.org/10.1097/GME.0b013e318193c48b.
6. Greene AD, Patounakis G, Segars JH. Genetic associations with diminished ovarian reserve: a systematic review of the literature. J Assist Reprod Genet. 2014;31(8):935–46. https://doi.org/10.1007/s10815-014-0257-5.
7. Lin W, Titus S, Moy F, Ginsburg ES, Oktay K. Ovarian aging in women with BRCA germline mutations. J Clin Endocrinol Metab. 2017;102(10):3839–47.
8. Emanuelli IP, Costa CB, Rafagnin Marinho LS, Seneda MM, Meirelles FV. Cumulus-oocyte interactions and programmed cell death in bovine embryos produced in vitro. Theriogenology. 2019;126:81–7. https://doi.org/10.1016/j.theriogenology.2018.11.028.
9. Almeida CP, Ferreira MCF, Silveira CO, Campos JR, Borges IT, Baeta PG, et al. Correlation of apoptosis in human granulosa cells—a review. Cell Biol Int. 2018;42(10):1276–81. https://doi.org/10.1002/cbin.11036.
10. Lee KS, Joo BS, Na YJ, Yoon MS, Choi OH, Kim WW. Cumulus cells apoptosis as an indicator to predict the quality of oocytes and the outcome of IVF-ET. J Assist Reprod Genet. 2001;18:490–8.
11. Oosterhuis GJ, Michgelsen HW, Lambalk CB, Schoemaker J, Vermani I. Apoptotic cell death in human granulosa-lutein cells: a possible indicator of in vitro fertilization outcome. Fertil Steril. 1998;70(4):747–9.
12. Lim AS, Tsakok MF. Age-related decline in fertility: a link to degenerative oocytes? Fertil Steril. 1997;68:265–71.
13. Clavero A, Castilla JA, Núñez AI, García-Peña ML, Maldonado V, Fontes J, et al. Apoptosis in human granulosa cells after induction of ovulation in women participating in an intracytoplasmatic sperm injection program. Eur J Obstet Gynecol Reprod Biol. 2003;110(2):181–5.
14. Regan SLP, Knight PG, Yovich JL, Stanger JD, Leung Y, Arfuso F, et al. The effect of ovarian reserve and receptor signalling on granulosa cell apoptosis during human follicle development. Mol Cell Endocrinol. 2018;470:219–27. https://doi.org/10.1016/j.mce.2017.11.002.
15. Hussein TS, Froiland DA, Amato F, Thompson JG, Gilchrist RB. Oocytes prevent cumulus cell apoptosis by maintaining a morphogenic paracrine gradient of bone morphogenetic proteins. J Cell Sci. 2005;118:5257–68.
16. Woo I, Christenson LK, Gunewardena S, Ingles SA, Thomas S, Ahmady A, et al. Micro-RNAs involved in cellular proliferation have altered expression profiles in granulosa of young women with diminished ovarian reserve. J Assist Reprod Genet. 2018;35(10):1777–86. https://doi.org/10.1007/s10815-018-1239-9.
17. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.
18. Crowley LC, Marfell BJ, Scott AP, Waterhouse NJ. Quantitation of apoptosis and necrosis by Annexin V binding, propidium iodide uptake, and flow cytometry. Cold Spring Harb Protoc. 2016;1(11). https://doi.org/10.1010/pdb.prot087288.
19. Barragán M, Pons J, Ferrer-Vaquero A, Cornet-Bartolomé D, Schweitzer A, Hubbard J, et al. The transcriptome of human oocytes is related to age and ovarian reserve. Mol Hum Reprod. 2017;23(8):535–48. https://doi.org/10.1038/1 Moorel/re/gax033.
20. Gurtcheff SE, Klein NA. Diminished ovarian reserve and infertility. Clin Obstet Gynecol. 2011 Dec;54(4):666–74. https://doi.org/10.1016/j.ajog.2018.11.028.
21. Sadrabadi SH, Saito H, Kaneko T, Saito T, Hiroi M. Effects of aging on ovarian fecundity in terms of the incidence of apoptotic granulosa cells. J Assist Reprod Genet. 2000;17(3):168–73.
22. Requena A, Cruz M, Agudo D, Pacheco A, García-Velasco JA. Type of gonadotropin during controlled ovarian stimulation affects the endocrine profile in follicular fluid and apoptosis rate in cumulus cells. Eur J Obstet Gynecol Reprod Biol. 2016;197:142–6. https://doi.org/10.1016/j.ejogrb.2015.12.018.
23. Jancar N, Kopitar AN, Ihan A, Bokal EV. Effect of apoptosis and reactive oxygen species production in human granulosa cells on oocyte fertilization and blastocyst development. J Assist Reprod Genet. 2007;24(2–3):91–7.
24. Li R, Albertini DF. The road to maturation: somatic cell interaction and self-organization of the mammalian oocyte. Nat Rev Mol Cell Biol. 2013;14(3):141–52. https://doi.org/10.1038/nrm3531.
25. Boucret L, Chao de la Barca JM, Morinière C, Desquiere V, Ferré-L’Hotellier V, Descamps P, et al. Relationship between diminished ovarian reserve and mitochondrial biogenesis in cumulus cells. J Assist Reprod Genet. 2016;33(11):486–93. https://doi.org/10.1007/s10815-016-0751-8.
26. Desquere-Dumas V, Clément A, Seegers V, Bouret L, Ferré-L’Hotellier V, Bouet PE, et al. The mitochondrial DNA content of cumulus cells is related to age and ovarian reserve. Eur J Obstet Gynecol Reprod Biol. 2016;197:142–6. https://doi.org/10.1016/j.ejogrb.2015.12.018.
27. Jancar N, Kopitar AN, Ihan A, Bokal EV. Effect of apoptosis and reactive oxygen species production in human granulosa cells on oocyte fertilization and blastocyst development. J Assist Reprod Genet. 2007;24(2–3):91–7.
28. Li R, Albertini DF. The road to maturation: somatic cell interaction and self-organization of the mammalian oocyte. Nat Rev Mol Cell Biol. 2013;14(3):141–52. https://doi.org/10.1038/nrm3531.
29. Boucret L, Chao de la Barca JM, Morinière C, Desquiere V, Ferré-L’Hotellier V, Descamps P, et al. Relationship between diminished ovarian reserve and mitochondrial biogenesis in cumulus cells. Hum Reprod. 2015;30(7):1653–6. https://doi.org/10.1093/humrep/dev148.
30. Desquiere-Dumas V, Clément A, Seegers V, Bouret L, Ferré-L’Hotellier V, Bouet PE, et al. The mitochondrial DNA content of cumulus cells is linked to embryo quality. Hum Reprod. 2017;32(3):607–14. https://doi.org/10.1093/humrep/dew341.
31. Uyar A, Torrealday S, Selc E. Cumulus and granulosa cell markers of oocyte and embryo quality. Fertil Steril. 2013;99(4):979–97. https://doi.org/10.1016/j.fertnstert.2013.01.129.
28. Adriaenssens T, Van Vaerenbergh I, Coucke W, Segers I, Verheyen G, Anckaert E, et al. Cumulus-corona gene expression analysis combined with morphological embryo scoring in single embryo transfer cycles increased live birth after fresh transfer and decreases time to pregnancy. J Assist Reprod Genet. 2019. https://doi.org/10.1007/s10815-018-01398-2.

29. Laven JS, Fauser BC. What role of estrogens in ovarian stimulation. Maturitas. 2006;54(4):356–62.

30. Walters KA, Eid S, Edwards MC, Thuis-Watson R, Desai R, Bowman M, et al. Steroid profiles by liquid chromatography-mass spectrometry of matched serum and single dominant ovarian follicular fluid from women undergoing IVF. Reprod BioMed Online. 2019;38(1):30–7. https://doi.org/10.1016/j.rbmo.2018.10.006.

31. Hossein G, Arabzadeh S, Hossein-Rashidi B, Hosseini MA. Relations between steroids and AMH: impact of basal and intrafollicular steroids to AMH ratios on oocyte yield and maturation rate in women with or without polycystic ovary undergoing in vitro fertilization. Gynecol Endocrinol. 2012;28(6):413–7. https://doi.org/10.3109/09513590.2011.613964.

32. Park EJ, Shin JW, Seo YS, Kim DW, Hong SY, Park WI, et al. Gonadotropin-releasing hormone-agonist induces apoptosis of human granulosa-luteal cells via caspase-8, -9 and -3, and poly-(ADP-ribose)-polymerase cleavage. Biosci Trends. 2011;5(3):120–8.

33. Ma M, Wang J, Xu L, Zhang Q, DU B, Jiang X, et al. Effects of two human chorionic gonadotropin doses administered to the ovarian states during the in vitro fertilization and embryo transfer program. Biomed Rep. 2015;3(2):215–9 Epub 2014 Nov 20.

34. Hassun Filho PA, Ribeiro MA, da Rocha AM, Allegreti JR, Serafini PC, da Motta EL. Effect of GnRH down-regulation on cumulus cell viability and apoptosis as measured by fluorescence-activated cell sorting. J Assist Reprod Genet. 2008;25(9–10):467–71. https://doi.org/10.1007/s10815-008-9263-9 Epub 2008 Oct 21.

35. Kaneko T, Saito H, Takahashi T, Ohta N, Saito T, Hiroi M. Effects of controlled ovarian hyperstimulation on oocyte quality in terms of the incidence of apoptotic granulosa cells. J Assist Reprod Genet. 2000;17(10):580–5.

36. Regan SL, Knight PG, Yovich JL, Stanger JD, Leung Y, Arfuso F, et al. Infertility and ovarian follicle reserve depletion are associated with dysregulation of the FSH and LH receptor density in human antral follicles. Mol Cell Endocrinol. 2017;446:40–51. https://doi.org/10.1016/j.mce.2017.02.007 Epub 2017 Feb 7.

37. Bencomo E, Pérez R, Arteaga MF, Acosta E, Peña O, Lopez L, et al. Apoptosis of cultured granulosa-lutein cells is reduced by insulin-like growth factor I and may correlate with embryo fragmentation and pregnancy rate. Fertil Steril. 2006;85(2):474–80.

38. Corn CM, Hauser-Kronberger C, Moser M, Tews G, Ebner T. Predictive value of cumulus cell apoptosis with regard to blastocyst development of corresponding gametes. Fertil Steril. 2005;84:627–33.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.